Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wedge, S. R.
Right arrow Articles by Wadsworth, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wedge, S. R.
Right arrow Articles by Wadsworth, P. F.
[Cancer Research 60, 970-975, February 15, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy

Stephen R. Wedge1, Donald J. Ogilvie, Michael Dukes, Jane Kendrew, Jon O. Curwen, Laurent F. Hennequin, Andrew P. Thomas, Elaine S. E. Stokes, Brenda Curry, Graham H. P. Richmond and Peter F. Wadsworth

Departments of Cancer and Infection Research [S. R. W., D. J. O., M. D., J. K., J. O. C., B. C., A. P. T., E. S. E. S.] and Safety of Medicines [G. H. P. R., P. F. W.], AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom, and AstraZeneca Pharma, Centre de Recherches, 51064 Reims, France [L. F. H.]

There is evidence that vascular endothelial growth factor (VEGF) contributes to solid tumor growth through the promotion of both angiogenesis and tumor vascular permeability. To abrogate VEGF signaling, we developed a small molecular weight inhibitor of VEGF receptor tyrosine kinase (RTK) activity that was compatible with chronic oral administration. ZD4190, a substituted 4-anilinoquinazoline, is a potent inhibitor of KDR and Flt-1 RTK activity, and VEGF stimulated HUVEC proliferation in vitro. Chronic once-daily oral dosing of ZD4190 to young rats produced a dose-dependent increase in the femoral epiphyseal growth plate area, which may be attributed to the inhibition of VEGF signaling in vivo because vascular invasion of cartilage is a prerequisite to the process of ossification. Once-daily oral dosing of ZD4190 to mice bearing established (~0.5 cm3) human tumor xenografts (breast, lung, prostate, and ovarian) elicited significant antitumor activity and at doses that would not be expected to have any direct antiproliferative effect on tumor cells. Prolonged tumor cytostasis was further demonstrated in a PC-3 xenograft model with 10 weeks of ZD4190 dosing, and upon withdrawal of therapy, tumor growth resumed after a short delay. These observations are entirely consistent with the proposed mode of action. ZD4190 is one of a series of VEGF RTK inhibitors that may have utility in the treatment of a range of histologically diverse solid tumor types.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
K. F. Byth, A. Thomas, G. Hughes, C. Forder, A. McGregor, C. Geh, S. Oakes, C. Green, M. Walker, N. Newcombe, et al.
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Mol. Cancer Ther., July 1, 2009; 8(7): 1856 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. S. Morrison, S.-A. Ricketts, J. Barnett, A. Cuthbertson, J. Tessier, and S. R. Wedge
Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy
J. Nucl. Med., January 1, 2009; 50(1): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J Ultrasound MedHome page
D. J. Lee, A. Lyshchik, J. Huamani, D. E. Hallahan, and A. C. Fleischer
Relationship Between Retention of a Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-Targeted Ultrasonographic Contrast Agent and the Level of VEGFR2 Expression in an In Vivo Breast Cancer Model
J. Ultrasound Med., June 1, 2008; 27(6): 855 - 866.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Cai and X. Chen
Multimodality Molecular Imaging of Tumor Angiogenesis
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
K. Frazier, R. Thomas, M. Scicchitano, R. Mirabile, R. Boyce, D. Zimmerman, E. Grygielko, J. Nold, A.-C. DeGouville, S. Huet, et al.
Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats
Toxicol Pathol, February 1, 2007; 35(2): 284 - 295.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Cai, K. Chen, K. A. Mohamedali, Q. Cao, S. S. Gambhir, M. G. Rosenblum, and X. Chen
PET of Vascular Endothelial Growth Factor Receptor Expression
J. Nucl. Med., December 1, 2006; 47(12): 2048 - 2056.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Cai, J. Rao, S. S. Gambhir, and X. Chen
How molecular imaging is speeding up antiangiogenic drug development.
Mol. Cancer Ther., November 1, 2006; 5(11): 2624 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q.-D. Nguyen, S. Rodrigues, C. M. Rodrigue, C. Rivat, C. Grijelmo, E. Bruyneel, S. Emami, S. Attoub, and C. Gespach
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Mol. Cancer Ther., August 1, 2006; 5(8): 2070 - 2077.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Troiani, O. Lockerbie, M. Morrow, F. Ciardiello, and S. G. Eckhardt
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Mol. Cancer Ther., July 1, 2006; 5(7): 1883 - 1894.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Hall, F. R. Westwood, and P. F. Wadsworth
Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate
Toxicol Pathol, February 1, 2006; 34(2): 131 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Brown, C. L. Courtney, L. M. King, S. C. Groom, and M. J. Graziano
Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor
Toxicol Pathol, June 1, 2005; 33(4): 449 - 455.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. G. Lloyd, B. M. Prior, H. Li, H. T. Yang, and R. L. Terjung
VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats
Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H759 - H768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Nicholson, K. Gulding, M. Conaway, S. R. Wedge, and D. Theodorescu
Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach
Clin. Cancer Res., December 15, 2004; 10(24): 8728 - 8734.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Sun, M. A. Blaskovich, R. K. Jain, F. Delarue, D. Paris, S. Brem, M. Wotoczek-Obadia, Q. Lin, D. Coppola, K. Choi, et al.
Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor
Cancer Res., May 15, 2004; 64(10): 3586 - 3592.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Beebe, J. P. Jani, E. Knauth, P. Goodwin, C. Higdon, A. M. Rossi, E. Emerson, M. Finkelstein, E. Floyd, S. Harriman, et al.
Pharmacological Characterization of CP-547,632, a Novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for Cancer Therapy
Cancer Res., November 1, 2003; 63(21): 7301 - 7309.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Ueda, T. Yamagishi, K. Samata, H. Ikeya, N. Hirayama, H. Takashima, S. Nakaike, M. Tanaka, and I. Saiki
A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155
Mol. Cancer Ther., November 1, 2003; 2(11): 1105 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D. J. McConkey
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
Mol. Cancer Ther., September 1, 2003; 2(9): 835 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. M. Veneziani, G. Fontanini, A. R. Bianco, et al.
Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase
Clin. Cancer Res., April 1, 2003; 9(4): 1546 - 1556.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
R. T. Ballock and R. J. O'Keefe
The Biology of the Growth Plate
J. Bone Joint Surg. Am., March 31, 2003; 85(4): 715 - 726.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A. J. Ryan, G. Fontanini, A. Fusco, and M. Santoro
ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases
Cancer Res., December 15, 2002; 62(24): 7284 - 7290.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Gomez, C. Simon, J. Remohi, and A. Pellicer
Vascular Endothelial Growth Factor Receptor-2 Activation Induces Vascular Permeability in Hyperstimulated Rats, and this Effect Is Prevented by Receptor Blockade
Endocrinology, November 1, 2002; 143(11): 4339 - 4348.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. C. Jayson, J. Zweit, A. Jackson, C. Mulatero, P. Julyan, M. Ranson, L. Broughton, J. Wagstaff, L. Hakannson, G. Groenewegen, et al.
Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies
J Natl Cancer Inst, October 2, 2002; 94(19): 1484 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, et al.
VEGF-Trap: A VEGF blocker with potent antitumor effects
PNAS, August 20, 2002; 99(17): 11393 - 11398.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J. A. Jackson, S. J. Boffey, P. J. Valentine, J. O. Curwen, H. L. Musgrove, et al.
ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration
Cancer Res., August 15, 2002; 62(16): 4645 - 4655.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Conti
Vascular Endothelial Growth Factor: Regulation in the Mouse Skin Carcinogenesis Model and Use in Antiangiogenesis Cancer Therapy
Oncologist, August 1, 2002; 7(90003): 4 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. L. Reimer, N. Agata, J. G. Tammam, M. Bamberg, W. M. Dickerson, G. D. Kamphaus, S. L. Rook, M. Milhollen, R. Fram, R. Kalluri, et al.
Antineoplastic Effects of Chemotherapeutic Agents Are Potentiated by NM-3, an Inhibitor of Angiogenesis
Cancer Res., February 1, 2002; 62(3): 789 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, March 22, 2001; (2001) 81615298.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, April 10, 2001; 98(8): 4605 - 4610.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.